Kurome Therapeutics has raised $15 million to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms. Medicxi and Affinity Asset Advisors co-led the series A round to fund Kurome through IND-enabling studies.
Nearly a year after emerging from a Versant Ventures incubator, Bright Peak Therapeutics is reeling in a $107 million series B. The funding will advance Bright Peak’s pipeline of cytokine medicines toward the clinic and build out its underlying technology, though the company is keeping details close to the vest.
Flagship Pioneering united its “intersystems biology” efforts under one roof last fall, and, now, that company is gearing up for human trials. With a $55 million boost, Senda Biosciences will push three programs into the clinic in 2022, including treatments for chronic kidney disease and metabolic diseases as well as an asset aimed at making checkpoint inhibitors work for more people.
Investor interest in Alzheimer’s ‘changed on the dime’ following FDA’s decision on Biogen’s aducanumab
The conditional approval of Biogen’s Aduhelm (aducanumab) might have been controversial, but the FDA’s decision on Monday could spur a renaissance of sorts for the Alzheimer’s space after a “decade of a big hole.”
Synthekine scaled another rung on its quest to becoming a “category-defining cytokine company” with a $107.5 million series B A the preclinical company joins a crop of biotechs breaking into the cytokine space.
Alcyone Therapeutics hopes to be a standout star and rising goddess in the central nervous system (CNS) treatment landscape.
Another day, another SPAC deal. Three months after extending its crossover round to $300 million, Valo Health unveiled plans to go public by merging with a special purpose acquisition company formed by Khosla Ventures.
More than two and a half years after raising an $80 million series D, ViaCyte has expanded the round with a $45 million financing tranche.
No lab? No problem, thanks to the wonders of modern technology. A platform developed by Menlo Park, California-based startup Strateos allows life sciences researchers to conduct experiments and analyses from anywhere in the world, with a little help from some robotic friends.
Kojin Therapeutics has raised $60 million to use iron-dependent cell death to treat drug-resistant cancer. The series A round positions the biotech to build on the work its scientific founders did at institutions including Harvard University and the Dana-Farber Cancer Institute.